KimSOhulchanskyyTYPudavarHE. Organically modified silica nanoparticles co-encapsulating photosensitizing drug and aggregation-enhanced two-photon absorbing fluorescent dye aggregates for two-photon photodynamic therapy. J Am Chem Soc2007;129:2669–2675.
WangHWZhuTCPuttME. Broadband reflectance measurements of light penetration, blood oxygenation, hemoglobin concentration, and drug concentration in human intraperitoneal tissues before and after photodynamic therapy. J Biomed Opt2005;10:14004.
ZhuTCFinlayJCHahnSM. Determination of the distribution of light, optical properties, drug concentration, and tissue oxygenation in-vivo in human prostate during motexafin lutetium-mediated photodynamic therapy. J Photochem Photobiol B2005;79:231–241.
FriedbergJSMickRStevensonJP. Phase II trial of pleural photodynamic therapy and surgery for patients with non-small-cell lung cancer with pleural spread. J Clin Oncol2004;22:2192–2201.
WangKKFinlayJCBuschTM. Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling. J Biophotonics2010;3:304–318.
MitraSFosterTH. Photophysical parameters, photosensitizer retention and tissue optical properties completely account for the higher photodynamic efficacy of meso-tetra-hydroxyphenylchlorin vs Photofrin. Photochem Photobiol2005;81:849–859.
GeorgakoudiINicholsMGFosterTH. The mechanism of Photofrin photobleaching and its consequences for photodynamic dosimetry. Photochem Photobiol1997;65:135–144.